A case of lupus‐like syndrome in a patient receiving adalimumab and a brief review of the literature on drug‐induced lupus erythematosus
Summary What is known and objective Drug‐induced lupus erythematosus occurs with some drugs and resolves with their withdrawal. Anti‐TNF therapies have been found to be associated with a lupus‐like syndrome, which is clinically distinct from classical drug‐induced as well as idiopathic lupus erythem...
Gespeichert in:
Veröffentlicht in: | Journal of clinical pharmacy and therapeutics 2017-06, Vol.42 (3), p.363-366 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Summary
What is known and objective
Drug‐induced lupus erythematosus occurs with some drugs and resolves with their withdrawal. Anti‐TNF therapies have been found to be associated with a lupus‐like syndrome, which is clinically distinct from classical drug‐induced as well as idiopathic lupus erythematosus.
Case description
We describe a case of a patient with severe psoriasis, who developed muscle pain with paraesthesia accompanied by ANA titres elevation with adalimumab treatment. The condition resolved after adalimumab cessation, and the patient was started on ustekinumab with good results.
What is new and conclusion
Ustekinumab might be a useful treatment option for patients with a history of TNF‐induced lupus‐like syndrome.
Drug‐induced lupus erythematosus is a lupus‐like syndrome similar to idiopathic lupus erythematosus that occurs when certain drugs are taken and resolves after their withdrawal. Anti‐TNF α therapies have been found to be associated with a lupus‐like syndrome, which is clinically distinct from both classical drug‐induced lupus erythematosus and idiopathic form. We describe a case of a female patient with severe psoriasis, who developed muscle pain with paraesthesia accompanied by ANA titres elevation under adalimumab treatment. The condition resolved after adalimumab cessation. |
---|---|
ISSN: | 0269-4727 1365-2710 |
DOI: | 10.1111/jcpt.12506 |